Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase II Bortezomib Maintenance in High-risk DLBCL
KCT0003987Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Janssen Pharmaceutical. Started May 2014; status: recruiting.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0003987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003987.